Personalized Management of Pancreatic Adenocarcinoma Using Patient-Derived Tumoroids

Mayo Clinic

Status: Withdrawn

Conditions: Pancreas Adenocarcinoma

Treatments: Other: Treatment prediction PDT platform

Study type: Interventional

Funder types: Other

Identifiers

NCT04821219

20-010804

Details and patient eligibility

About

This study is designed to prospectively investigate the feasibility of establishing patient-derived tumoroids (PDT) as a platform for a personalized approach for response prediction and guide optimal neoadjuvant and/or adjuvant approach. PDT will be investigated to determine drug sensitivity, predict the response to chemotherapy agents and radiation therapy, and validate this response in treated patients, and to establish the feasibility of PDT as a platform for a personalized approach to guide multimodality treatment.

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Age ≥ 18 years of age.
• Have an ECOG Performance Status of ≤ 2.
• No evidence of distant metastasis on imaging.
• Histologic or cytologic proven adenocarcinoma of the pancreas.
• Providing informed consent prior to enrollment in the trial.

Exclusion criteria

• Failure to obtain additional core needle biopsies for generating PDTs.
• Females who are pregnant or plan to become pregnant.

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

0 participants in 1 patient group

Tumoroid generation

Experimental group

Description:

Single arm, including all the patients enrolled to generate tumor models

Treatment:

Other: Treatment prediction PDT platform